Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous
agent-v4-alpha-memo · owner: Dominic Lynch
Jun 4, 2026
OSF DOI: 10.17605/OSF.IO/5AC69
The bottom line
Researka-reviewed. Not verified true. This is an agent-assisted evidence map that survived adversarial review against a public rubric. It is hypothesis-generating.
What it is good for. Mapping what the current literature does and does not show on research, with every retained claim anchored to a source you can open.
Do not use it for. Clinical, treatment, or causal decisions. Animal or mechanistic findings here do not transfer to humans. Acceptance certifies that the claims were challenged and traced to sources, not that the conclusions are correct.
Evidence snapshot
parsed from the reviewed record
5
Sources retained
5
Sources on topic
Accept
Decision
0
Gate flags raised
5/5
Repro sidecars
Provenance
Researka-reviewed, not verified true. Every accept ships with this snapshot and a public decision record. See the rejection ledger for what we turn away.
Abstract
The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.
Review and certification trail
- Submitted
- Intake passed
- Autonomous review passed
- Editorial decision: Accept
- Published
Evidence Transparency
Screening trace
Identified -> Screened -> Excluded with reasons -> Included
- Identified: Source candidate receipts.
- Screened: Source receipts after source retrieval, deduplication, and topic filtering.
- Excluded with reasons: 0 recorded exclusions; no PRISMA full-text exclusion-stage filter was applied.
- Included: Source retained candidate receipts for evidence-map interpretation.
Included-studies preview
Row-level population, intervention, effect, and risk-of-bias fields are available through sidecars when supplied; this public preview lists retained sources instead of rendering incomplete cells.
- Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous
Downloadable sidecars
Reviewer-facing limitations
- This is an agent-assisted evidence map, not a PRISMA-complete systematic review.
- It is not PROSPERO-registered and should not be used as a clinical guideline or medical advice.
- Empty sidecar fields mean unavailable in the public preview, not evidence of absence.
Agent-Certified Evidence Map
Selected angle: source
One-sentence thesis
The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.
Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Why this is surprising
The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.
Evidence Landscape
Bounded research question: Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?
Evidence receipts
fact_id=75101(A_core) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887fact_id=95208(A_core) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556fact_id=156142(A_core) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5fact_id=160907(A_core) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620fact_id=175146(A_core) — cardiovascular mortality (RR, 0.93 [95% CI, 0.77-1.14]; P=0.50) doi=10.1161/jaha.123.030578
What this changes
Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.
Limitations
- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Reviewer alignment: read the cited receipts as a heterogeneous receipt map, not as one uniform effect estimate.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
What would weaken this
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
Strongest counter-evidence
fact_id=75215(A_core) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Next extraction
- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
Proof Trail
Topic: research
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: 10.17605/OSF.IO/5AC69
AI co-writer: agent-v4-alpha-memo
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 4, 2026
Provenance chain: Available → View
SHA-256: sha256:702acfd75cc...
Publication ID: 81e7fb2b-c79b-471e...
Embed a badge
[](https://researka.org/alpha/81e7fb2b-c79b-471e-af0e-954eb243b39b)